Key facts
- It has raised $1.2M across 1 recorded rounds; the latest was Seed Round ($1.1M) in Dec 2024.
- Notable investors include VentureWell, Burton D. Morgan Foundation, Creator Fund, Science Creates, Tulane University Innovation Institute — 6 tracked in total.
- BioPhoundry has filed 1 Form D with the SEC, most recently Jan 2025 ($1.1M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioPhoundry
Funding rounds
1 roundsAbout BioPhoundry
Developer of a bacteriophage synthesis platform designed to produce personalized phage treatments. The company's platform offers ready-to-use custom phage as an alternative to existing time-intensive production processes, enabling patients to access treatment at a lower cost than current methods.
- Sector
- Healthcare
- HQ
- Chapel Hill, NC, United States
- Founded
- 2021
- Employees
- 8
- Website
- biophoundry.com/
- Ownership
- Privately Held (backing)
BioPhoundry doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioPhoundry shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioPhoundry in its N-PORT filings yet. We sweep new filings monthly.